Oncolytic Virus Therapy Market Analysis

End User Segment Analysis 

The hospitals segment is estimated to account for the largest share of 67% in the oncolytic virotherapy market over the discussed timeframe. Hospitals will continue to dominate the end-use segment due to their capacity to administer biologics, their oncology specialty and expertise, their allocation of resources to clinical research, and their ability to provide a complete patient access pathway. Hospital-based oncology centers often access more complex therapies sooner than hospital-affiliated community oncologists, as well as have a more elaborate trial process for new oncolytic agents. These advantages of hospitals will lead to increased patient access to oncolytic viruses for their comprehensive treatment approaches.

Type Segment Analysis  

The genetically engineered viruses segment is poised to dominate the market. Genetically engineered viruses are at the forefront of development because they can be designed to target tumors more precisely than other options. Moreover, they potentially could make the treatment safer by transferring genes to reduce off-target effects, and they can improve immune activation. Clinical developments such as talimogene laherparepvec (T-VEC) also illustrate the relevance of genetic modifications, and indicate that the modifications could make treatment safer and more effective in human trials

Application Segment Analysis  

The solid tumors segment is likely to grasp a substantial share of the market. Solid tumors are by far the largest application segment, based on the high global incidence of breast, lung, and prostate cancers. Oncolytic viruses can infiltrate tumor microenvironments and replicate instead of favorably, where conventional treatments may fail. With advanced solid tumours on the rise, the need for alternative locoregional treatments is warranted.

Our in-depth analysis of the oncolytic virotherapy market includes the following segments: